Trial Profile
A Phase I/II Study of Duvelisib and Venetoclax in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma or Patients With Richter's Syndrome
Status:
Recruiting
Phase of Trial:
Phase I/II
Latest Information Update: 11 Jan 2024
Price :
$35
*
At a glance
- Drugs Duvelisib (Primary) ; Venetoclax (Primary)
- Indications Chronic lymphocytic leukaemia; Diffuse large B cell lymphoma; Richter's syndrome
- Focus Adverse reactions; Therapeutic Use
- 31 Jul 2023 Planned End Date changed from 1 Jul 2025 to 1 Jul 2026.
- 31 Jul 2023 Planned primary completion date changed from 1 Jul 2023 to 1 Jul 2024.
- 13 Dec 2022 Updated results (As of July 13, 2022, n=43) with 2 yrs median follow-up were presented at the 64th American Society of Hematology Annual Meeting and Exposition.